3-cyclopentyl-3-(4-(2-(4-((3-endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carbonyl)phenylamino)pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile | 1153941-80-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-cyclopentyl-3-(4-(2-(4-((3-endo)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carbonyl)phenylamino)pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile
• CAS: 1153941-80-0
• 化学式: C₂₉H₃₃N₇O₂
• 分子量: 511.627
• InChiKey: MXQINOUZZKFKCA-CPYPIWFDSA-N

物化性质

• 沸点：
  801.8±75.0 °C(predicted)
• 密度：
  1.42±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  38.0
• 可旋转键数：
  7.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  119.96
• 氢给体数：
  2.0
• 氢受体数：
  8.0

文献信息

• JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
  申请人：Incyte Corporation

  公开号：US20170087158A1

  公开（公告）日：2017-03-30

  The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.

  本申请涉及Janus激酶（JAK）抑制剂，包括3-环戊基-3- [4-（7H-吡咯[2,3-d]嘧啶-4-基）-1H-吡唑-1-基]丙腈，用于治疗干眼症或改善干眼症的特定症状，如眼部不适，视觉障碍，泪膜不稳定，泪液高渗性和眼表炎症，以及相关的套件和组合物，包括局部组合物。
• 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS
  申请人：Li Yun-Long

  公开号：US20090318405A1

  公开（公告）日：2009-12-24

  The present invention provides substituted bicyclic heteroaryl compounds, including, for example, 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了替代的双环杂环芳基化合物，包括例如4-吡唑基-N-芳基嘧啶-2-胺和4-吡唑基-N-杂环芳基嘧啶-2-胺，这些化合物可以调节激酶的活性，对于与激酶活性相关的疾病的治疗具有用处，包括例如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。
• US8309718B2
  申请人：——

  公开号：US8309718B2

  公开（公告）日：2012-11-13
• [EN] METHOD OF TREATING MUSCULAR DEGRADATION<br/>[FR] PROCÉDÉ DE TRAITEMENT D'UNE DÉGRADATION MUSCULAIRE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2013173506A2

  公开（公告）日：2013-11-21

  A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such as may result from ventilation.